pharma · Duchenne Muscular Dystrophy · Muscular Dystrophies · CAPR
CAPRICOR THERAPEUTICS
CAPRICOR THERAPEUTICS, INC.
CAPRICOR THERAPEUTICS is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker CAPR. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophies, Covid19, Dil
San Diego, USA HQ
2005 Founded
240 Employees
Public company Type
CAPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2005
- Employees
- 240
- Programs
- 8
- Drugs
- 6
- Patents
- 43
Deramiocel (CAP-1002)
Phase 3 · mab · Muscular Dystrophies
Deramiocel (CAP-1002) for Muscular Dystrophies is a Phase 3 program (mab) at CAPRICOR THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Internal code CAP-1002-DMD-04
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CAPRICOR THERAPEUTICS, INC.
- Phase
- Phase 3
- Modality
- mab
- Indication
- Muscular Dystrophies
- Status
- active
- Trials
- 1